Making Sense of the Latest Alzheimer’s Research

With a keen and critical eye, you can tell if that trending Alzheimer’s story is a major breakthrough.

close up of fingers on keyboard

Updated on January 11, 2023.

You’re a pro at skimming: You check multiple news feeds daily, glance at headlines, and read just enough of each major story to stay informed. And when you come across a “game-changing” Alzheimer’s disease (AD) breakthrough, you might share the article with interested friends and family or head to the store for the latest food reputed to have Alzheimer’s-fighting powers.

Headlines were understandably ablaze in January 2023, when the United States Food & Drug Administration (FDA) approved lecanemab. Hailed as a game changer, the Alzheimer’s drug was one of the first to potentially slow the progression of cognitive decline. And in time, while lecanemab may well offer relief for people with Alzheimer’s, it’s important to remember it presents both benefits and risks, and is not a cure for the disease.

“Science is slow. Progress is built on small, incremental steps," explains Upinder Singh, MD, a doctor specializing in geriatrics at Southern Hills Hospital and Kindred Healthcare in Las Vegas, Nevada. "But researchers, doctors, and the media are all enthusiastic. Because of that enthusiasm, tiny steps are often called ‘major leaps’ or ‘breakthroughs.’ But be careful: don’t let the hype and hope outweigh reality.” 

Read past the headlines

When Alzheimer’s studies make the front page, it’s okay to share in the scientists’ excitement. But read the story carefully so you can decide for yourself whether it’s worth all the media buzz. Keep these hard-hitting questions in mind:

How advanced is the research?

Before a drug or a treatment can become available to the public, it must go through a series of studies to make sure it’s safe and effective for humans. An article may feature a drug that’s in the preclinical phase, which means it’s still being tested on cells or animals. If the animals don’t show any major side effects, it may be approved for clinical trials in humans.

There are four trial phases, each one involving more people than the one before it.

Phase one involves a small number of volunteers to test the safety of a drug at various doses. Phases two and three focus more on the drug’s effectiveness. If the drug is shown to be safe and effective in phases one through three, the FDA may approve it. After it becomes available on the market, researchers continue to track its safety among thousands of people over long periods of time (phase four).

“In each phase, the benefits have to significantly outweigh the risks for something to be called ‘medicine,’” says Dr. Singh. “Many drugs don’t make it because they show positive results in one phase, but don’t pan out later.”

Alzheimer’s drugs have an especially hard time reaching the market because even if a drug improves someone’s brain scans or brain chemistry, it won’t necessarily improve their symptoms or change the course of their disease.

Did the study look at what the headline’s claiming?

Make sure that the grabby headline matches the study’s findings. 

Did the researchers focus on a single Alzheimer’s symptom, but the headline claims there’s a cure?

Did the drug improve patients’ brain scans, but didn’t have a real impact on their memory?

“It’s important to ask if the study has any effect on what you’re trying to treat,” says Singh. “There may be a medicine that removes the tangles and plaques—proteins that build up in the brain to cause Alzheimer’s—and that’s very good. But if the drug doesn’t help you think or improve your symptoms, then it’s no use for you.” 

How Alzheimer’s research might work for you

If you read about a clinical trial that you’d like to sign up for—or that sounds like a good match for a friend or loved one—it’s good to start by finding out which company is funding it. Then ask your healthcare provider (HCP) for more information about the company and the trial and whether you might be eligible to participate. You can use the Alzheimer’s Association TrialMatch tool to compare trials and choose the best fit. You can also find out about trials through the National Institute of Aging’s clinical trials search tool.

With smart research and guidance from your HCP, you or a loved one may be able to take advantage of the exciting advances being made in Alzheimer’s science.

Article sources open article sources

U.S. Food & Drug Administration. FDA Grants Accelerated Approval for Alzheimer’s Disease Treatment. January 6, 2023. 
Van Dyck CH, Swanson CJ, et al. Lecanemab in Early Alzheimer’s Disease. New England Journal of Medicine. 2023; 388:9-21.
National Institute on Aging. What Are Clinical Trials and Studies? Content reviewed April 09, 2020.
Yiannopoulou KG, Anastasiou AI, et al. Reasons for Failed Trials of Disease-Modifying Treatments for Alzheimer Disease and Their Contribution in Recent Research. Biomedicines. 2019 Dec 9;7(4):97.
Maria Burk. Why Alzheimer’s drugs keep failing. Scientific American. July 14, 2014.

More On

How can we delay the onset of Alzheimer’s disease?

video

How can we delay the onset of Alzheimer’s disease?
Two activities have been shown to have more success at delaying Alzheimer's than anything else. HealthMaker Alvaro Fernandez explains what these helpf...
What is Agitation in Alzheimer’s Disease?

article

What is Agitation in Alzheimer’s Disease?
A guide to the symptoms and causes of episodes of agitation in people who have Alzheimer’s disease.
Diagnosed With Alzheimer’s? Ask Your Provider These 8 Questions

slideshow

Diagnosed With Alzheimer’s? Ask Your Provider These 8 Questions
Get the facts and learn ways to cope with this life-changing disease.
Is Alzheimer's Disease Hereditary?

video

Is Alzheimer's Disease Hereditary?
Neurologist and functional medicine expert Dr. David Perlmutter discusses whether or not Alzheimer's disease is hereditary. Watch Dr. Perlmutter's vid...
Study examines possible cause of Alzheimer’s

video

Study examines possible cause of Alzheimer’s
Alzheimer’s disease is the most common type of dementia. A substance called beta-amyloid is the cause and early treatment to prevent the decline of am...